A modified IGF-1 that lasts 20+ hours instead of 10 minutes. More potent anabolic signaling — and more risk. Here's what you need to know before researching this compound.
Research context only. IGF-1 LR3 carries significant hypoglycemia risk. Research use requires careful dosing and glucose monitoring. Not medical advice.
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a modified analog of IGF-1 — a hormone naturally produced in the liver in response to growth hormone. The "LR3" modification replaces glutamic acid at position 3 with arginine and adds a 13 amino acid extension to the N-terminus. These changes dramatically reduce IGF-1's binding to IGF binding proteins (IGFBPs) in the blood, extending its half-life from roughly 10 minutes to approximately 20–30 hours.
The result is a compound with the same muscle-building mechanism as natural IGF-1 but with sustained activity — a single injection provides anabolic signaling throughout the day rather than a brief pulse.
The one-line version: IGF-1 LR3 is a long-acting version of the body's primary muscle-building hormone that acts directly on muscle cells — activating protein synthesis, muscle cell proliferation, and satellite cell recruitment — for 20+ hours per injection rather than the 10 minutes of natural IGF-1.
The most important thing to know upfront: IGF-1 LR3 carries meaningful hypoglycemia risk. It activates the same receptors as insulin and can significantly lower blood glucose, especially in fasted or post-workout states. This is the primary safety consideration — not a minor footnote. Research requires glucose monitoring.
IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) on muscle cells with high affinity. IGF-1R activation triggers the PI3K/Akt/mTOR pathway — the central signaling cascade for muscle protein synthesis.
mTOR activation increases ribosomal activity and protein translation — the cellular process of building new muscle proteins. This is the primary anabolic mechanism shared with insulin and HGH-driven IGF-1.
IGF-1 activates muscle satellite cells — the stem cells responsible for muscle repair and hypertrophy. Satellite cell proliferation and fusion into existing muscle fibers is how muscles actually grow in size, not just get stronger. This mechanism is distinct from the acute protein synthesis effects.
IGF-1's satellite cell activation can theoretically drive muscle hyperplasia (new fiber creation) in addition to hypertrophy (existing fiber growth). This is the basis for claims that IGF-1 produces different-quality muscle growth than HGH — though demonstrating true hyperplasia in adult humans is difficult.
Why LR3 specifically vs native IGF-1: Natural IGF-1 is rapidly bound by IGF binding proteins in the blood, reducing its free (active) concentration and limiting its half-life to minutes. LR3's modifications prevent this binding, keeping IGF-1 free and active for hours. You get the same mechanism with dramatically more sustained activity per injection.
Animal studies demonstrate clear anabolic effects from IGF-1 LR3: increased muscle mass, satellite cell proliferation, and improved recovery from muscle damage. The compound is used extensively in research settings for studying muscle biology and the IGF-1 axis.
Human data is primarily from observational sources — bodybuilding community use — rather than formal clinical trials. The mechanism is well-established from IGF-1 biology; the specific LR3 modification has solid pharmacological rationale. But there's no Phase 2/3 human trial data comparable to the GLP-1 or even healing peptide categories.
The cancer consideration: IGF-1 receptor signaling is a known promoter of cancer cell proliferation. Elevated IGF-1 levels are associated with increased risk of several cancers in epidemiological studies. Exogenous IGF-1 LR3 raises this concern more acutely than HGH-driven IGF-1 elevation, because it bypasses the natural regulatory mechanisms. This is the most significant long-term safety consideration.
Hypoglycemia protocol: Always have fast-acting carbohydrates available when using IGF-1 LR3. Inject post-workout with food, never in a fasted state or near bedtime. Symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) require immediate glucose consumption. Blood glucose monitoring before and after injection is strongly recommended in any research context.
They carry different risk profiles, not necessarily safer vs less safe. HGH carries insulin resistance, joint pain, and carpal tunnel risks. IGF-1 LR3 carries hypoglycemia and more direct cancer promotion risk. Neither is categorically safer — they're different compounds with different safety considerations.
IGF-1 receptor downregulation means extended cycles produce diminishing returns after 4–6 weeks. Longer cycles don't build more muscle — they primarily increase cumulative exposure to side effects. Short cycles with adequate off-time maintain receptor sensitivity and produce better overall outcomes.
Systemic subcutaneous injection distributes IGF-1 LR3 throughout the body via circulation. The idea that local IM injection 'directs' growth to a specific muscle isn't supported — anabolism is systemic. Local IM injection is sometimes used but the whole-body effect is the primary mechanism regardless of site.
COA-verified vendor pricing with promo codes and reconstitution guide.
View Pricing → Dosage Calculator